The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Real-world clinical outcomes in patients (pts) with HR+/HER2- metastatic breast cancer (mBC) treated with chemotherapy (CT) in the United States (US).
 
Sara M. Tolaney
Consulting or Advisory Role - 4D Pharma; AstraZeneca; Athenex; BeyondSpring Pharmaceuticals; Blueprint Medicines; Bristol-Myers Squibb; Certara Inc; Chugai Pharma; CytomX Therapeutics; Daiichi Sankyo; Eisai; Ellipses Pharma; G1 Therapeutics; Genentech; Immunomedics/Gilead; Infinity Pharmaceuticals; Kyowa Hakko Kirin; Lilly; Merck; Mersana; NanoString Technologies; Nektar; Novartis; Odonate Therapeutics; OncoPep; OncoSec; OncXerna Therapeutics; Paxman; Pfizer; Puma Biotechnology; Reveal Genomics; Samsung Bioepis; Sanofi; Seagen; Zentalis; Zymeworks
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Cyclacel (Inst); Eisai (Inst); Exelixis (Inst); Genentech/Roche (Inst); Immunomedics (Inst); Lilly (Inst); Merck (Inst); NanoString Technologies (Inst); Nektar (Inst); Novartis (Inst); Odonate Therapeutics (Inst); Pfizer (Inst); Sanofi (Inst); Seagen (Inst)
 
Kevin Punie
Honoraria - AstraZeneca; Exact Sciences; Focus Patient; Gilead Sciences; Gilead Sciences (Inst); Lilly; Lilly (Inst); Lilly (Inst); MSD; MSD (Inst); Mundipharma (Inst); Novartis; Novartis (Inst); Novartis (Inst); Pfizer; Pfizer; Pfizer (Inst); Pfizer (Inst); Roche; Roche (Inst); Seagen; Seagen (Inst)
Consulting or Advisory Role - AstraZeneca; AstraZeneca; AstraZeneca (Inst); Exact Sciences; Gilead Sciences; Lilly; Lilly (Inst); Lilly (Inst); MSD (Inst); Novartis; Novartis; Novartis; Novartis; Novartis; Novartis (Inst); Novartis (Inst); Novartis (Inst); Pfizer; Pierre Fabre (Inst); Roche; Roche (Inst); Roche (Inst); Roche (Inst); Sanofi; Seagen; Teva (Inst); Vifor Pharma (Inst)
Research Funding - MSD (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Novartis; Pfizer; PharmaMar; Roche; Roche; Roche; Roche
Other Relationship - Need
 
Allison W. Kurian
Other Relationship - Adela; Ambry Genetics; Color Genomics; GeneDx/BioReference; Genentech; InVitae; Myriad Genetics
 
Ioanna Ntalla
Employment - Gilead Sciences
Stock and Other Ownership Interests - Gilead Sciences
 
Wendy Verret
Employment - Gilead Sciences; Roche/Genentech
 
Natalia Sadetsky
Employment - Gilead Sciences
Stock and Other Ownership Interests - Gilead Sciences
 
Nikoleta Sjekloca
Employment - Gilead Sciences
Stock and Other Ownership Interests - Gilead Sciences
 
Michael Stokes
Consulting or Advisory Role - Gilead Sciences (Inst)
Research Funding - Gilead Sciences (Inst)
 
Komal L. Jhaveri
Consulting or Advisory Role - Abbvie; AstraZeneca; Biotheranostics; BluePrint Medicines; Bristol-Myers Squibb; Daiichi Sankyo; Genentech; Gilead Sciences; Intellisphere; Jounce therapeutics; Lilly; Novartis; Pfizer; Sanofi; Scorpion Therapeutics; Seagen; Sun Pharma Advanced Research Company; Synthon; Taiho Oncology
Research Funding - ADC Therapeutics (Inst); AstraZeneca (Inst); Clovis Oncology (Inst); Context Therapeutics (Inst); Debiopharm Group (Inst); Genentech (Inst); Immunomedics (Inst); Lilly (Inst); Novartis (Inst); Novita Pharmaceuticals (Inst); Pfizer (Inst); Puma Biotechnology (Inst); VelosBio/Merck (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Genentech/Roche; Gilead Sciences; Intellisphere; Jounce Therapeutics; Lilly; Pfizer; Taiho Pharmaceutical